Sponsored by		Sponsored by
Rimonabant Pre-meeting symposium		New concepts in the management of Type 2 diabetes: a DPP-4 inhibitor Pre-Symposium

14:00-16:00	■ Unmet clinical needs in		13:00-14:00	■ Lunch
	cardiometabolic risk reduction		14:00-14:30	■ Introduction and overview:
	in patients with abdominal			key limitations in the current
	obesity			therapies for Type 2 diabetes
	■  The role of rimonabant -			J. Davidson
	the first selective CB1 blocker		14:30-15:00	■ Dysregulation of insulin and
	- in lipid and glucose			glucagon in the pathogenesis
	metabolism: lessons from			of Type 2 diabetes
	animals and humans			P. Aschner
16:00-16:30	■  Coffee Break		15:00–15:10	Discussion and questions
16:30-17:30	■  Panel Discussion			P. Home
	Optimising the clinical		15:10–15:40	■  The emerging role of
	benefits of rimonabant:			incretin-related therapy in the
	identification of suitable			management of Type 2
	candidates for treatment			diabetes
				TBA
			15:40-16:10	■  An update on DPP-4
				inhibitors in the management
				of Type 2 diabetes - potential
				roles in monotherapy and
				combination therapy
				P. Stein
			16:10-16:30	■  Discussion and questions;
				summary
				J. Davidson
			16:30-17:00	■  Tea, coffee and dessert